Leading payer and health system stakeholders reviewed literature and shared insights on the value of real-time continuous glucose monitoring (rtCGM) in type 2 diabetes (T2D) population health.
Analysis of claims data showed reduced utilization and costs among patients with nonintensively treated type 2 diabetes (T2D) using self-monitoring of blood glucose compared with continuous glucose monitoring.